Hewei Ge

Chinese Academy Of Medical Sciences And Peking Union Medical College
Beijing, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Distinct immune microenvironment in HER2-low triple-negative breast cancer underlies inferior response to immunotherapy.

Distinct immune microenvironment in HER2-low triple-negative breast cancer underlies inferior response to immunotherapy.

Journal: NPJ precision oncology

Published: January 23, 2026

Machine learning survival model for personalised prevention of catheter-related thrombosis in tumour patients.

Machine learning survival model for personalised prevention of catheter-related thrombosis in tumour patients.

Journal: Communications medicine

Published: May 14, 2025

Multi-cohort validation of a lipid metabolism and ferroptosis-associated index for prognosis and immunotherapy response prediction in hormone receptor-positive breast cancer.

Multi-cohort validation of a lipid metabolism and ferroptosis-associated index for prognosis and immunotherapy response prediction in hormone receptor-positive breast cancer.

Journal: International journal of biological sciences

Published: March 04, 2025

Systemic immune characteristics predicting toxicity to immune checkpoint inhibitors in patients with advanced breast cancer.

Systemic immune characteristics predicting toxicity to immune checkpoint inhibitors in patients with advanced breast cancer.

Journal: Journal of autoimmunity

Published: January 30, 2025

Biologically-informed integration of drug representations for breast cancer treatment using deep learning.

Biologically-informed integration of drug representations for breast cancer treatment using deep learning.

Journal: Nature communications

Published: November 13, 2024

Predictive circulating biomarkers of the response to anti-PD-1 immunotherapy in advanced HER2 negative breast cancer.

Predictive circulating biomarkers of the response to anti-PD-1 immunotherapy in advanced HER2 negative breast cancer.

Journal: Clinical and translational medicine

Published: September 27, 2024

Meta-analysis reveals pathological complete response benefits from neoadjuvant immuno-chemotherapy combination in patients with HER2-negative breast cancer.

Meta-analysis reveals pathological complete response benefits from neoadjuvant immuno-chemotherapy combination in patients with HER2-negative breast cancer.

Journal: BMC cancer

Published: September 04, 2024

Comparative efficacy of anthracycline-free and anthracycline-containing neoadjuvant chemoimmunotherapy regimens for triple-negative breast cancer.

Comparative efficacy of anthracycline-free and anthracycline-containing neoadjuvant chemoimmunotherapy regimens for triple-negative breast cancer.

Journal: Translational oncology

Published: August 06, 2024

Genetic factors in the pathogenesis of cardio-oncology.

Genetic factors in the pathogenesis of cardio-oncology.

Journal: Journal of translational medicine

Published: April 07, 2024

Pyrotinib and trastuzumab combination treatment synergistically overcomes HER2 dependency in HER2-positive breast cancer: insights from the PHILA trial.

Pyrotinib and trastuzumab combination treatment synergistically overcomes HER2 dependency in HER2-positive breast cancer: insights from the PHILA trial.

Journal: EBioMedicine

Published: April 05, 2024

Metronomic chemotherapy plus anti-PD-1 in metastatic breast cancer: a Bayesian adaptive randomized phase 2 trial.

Metronomic chemotherapy plus anti-PD-1 in metastatic breast cancer: a Bayesian adaptive randomized phase 2 trial.

Journal: Nature medicine

Published: February 07, 2024

Applications of digital Medicine in oncology: Prospects and challenges.

Applications of digital Medicine in oncology: Prospects and challenges.

Journal: Cancer innovation

Published: October 13, 2022

Showing 1-12 of 12

Last Updated: 09/26/2026